Annelies van Vuren

Mrs. Annelies van Vuren


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SGSimon Grootendorst
Simon Grootendorst
JWJonathan de Wilde
Jonathan de Wilde
BDBirgit van Dooijeweert
Birgit van Dooijeweert
AVAnnelies van Vuren
Annelies van Vuren
WSWouter van Solinge
Wouter van Solinge
MBMarije Bartels
Marije Bartels
Rare hereditary anemias (RHA) represent a group of disorders characterized by either impaired production of erythrocytes or decreased survival (i.e., hemolysis). In RHA, the regulation of iron metabolism and erythropoiesis is often disturbed, leading to iron overload or worsening of chronic anemia due to unavailability of iron for erythropoiesis. Whereas iron overload generally is a well-recognized complication in patients requiring regular blood transfusions, it is also a significant problem in a large proportion of patients with RHA that are not transfusion dependent. This indicates that RHA share disease-specific defects in erythroid development that are linked to intrinsic defects in iron metabolism. In this review, we discuss the key regulators involved in the interplay between iron and erythropoiesis and their importance in the spectrum of RHA.

10 May 2022 in American Journal of Hematology
Verified
Journal Article
Open access
AVAnnelies van Vuren
Annelies van Vuren
JKJean Louis Kerkhoffs
Jean Louis Kerkhoffs
SSSaskia Schols
Saskia Schols
ARAnita Rijneveld
Anita Rijneveld
ENErfan Nur
Erfan Nur
EBEduard J. van Beers
Eduard J. van Beers
Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side‐effects, high costs, and the lack of availability in many countries with a high prevalence of hereditary anemias. In this phase III randomized placebo‐controlled trial, we assigned adults with non‐transfusion‐dependent hereditary anemias with mild‐to‐moderate iron overload to receive esomeprazole (at a dose of 40 mg twice daily) or placebo for 12 months in a cross‐over design. The primary end point was change of liver iron content measured by MRI. A total of 30 participants were enrolled in the trial. Treatment with esomeprazole resulted in a statistically significant reduction in liver iron content that was 0.55 mg Fe/g dw larger than after treatment with placebo (95%CI [0.05 to 1.06]; p = 0.03). Median baseline liver iron content at the start of esomeprazole was 4.99 versus 4.49 mg Fe/g dw at start of placebo. Mean delta liver iron content after esomeprazole treatment was −0.57 (SD 1.20) versus −0.11 mg Fe/g dw (SD 0.75) after placebo treatment. Esomeprazole was well tolerated, reported adverse events were mild and none of the patients withdrew from the study due to side effects. In summary, esomeprazole resulted in a significant reduction in liver iron content when compared to placebo in a heterogeneous group of patients with non‐transfusion‐dependent hereditary anemias. From an international perspective this result can have major implications given the fact that proton pump inhibitors may frequently be the only realistic therapy for many patients without access to or not tolerating iron chelators.

Verified
Journal Article
Open access
PDF file
AVAnnelies van Vuren
Annelies van Vuren
RWRichard van Wijk
Richard van Wijk
EBEduard J. van Beers
Eduard J. van Beers
Joannes MarxJoannes Marx
Joannes Marx
Patients with hereditary hemochromatosis and non-transfusion-dependent hereditary anemia develop predominantly liver iron-overload. We present a unique method allowing quantification of liver iron retention in humans during first-pass of 59Fe-labeled iron through the portal system, using standard ferrokinetic techniques measuring red cell iron uptake after oral and intravenous 59Fe administration. We present data from patients with iron deficiency (ID; N = 47), hereditary hemochromatosis (HH; N = 121) and non-transfusion-dependent hereditary anemia (HA; N = 40). Mean mucosal iron uptake and mucosal iron transfer (±SD) were elevated in patients with HH (59 ± 18%, 80 ± 15% respectively), HA (65 ± 17%, 74 ± 18%) and ID (84 ± 14%, 94 ± 6%) compared to healthy controls (43 ± 19%, 64 ± 18%) (p < 0.05) resulting in increased iron retention after 14 days compared to healthy controls in all groups (p < 0.01). The fraction of retained iron utilized for red cell production was 0.37 ± 0.17 in untreated HA, 0.55 ± 0.20 in untreated HH and 0.99 ± 0.22 in ID (p < 0.01). Interestingly, compared to red blood cell iron utilization after oral iron administration, red blood cell iron utilization was higher after injection of transferrin-bound iron in HA and HH. Liver iron retention was considerably higher in HH and HA compared to ID. We hypothesize that albumin serves as a scavenger of absorbed Fe(II) for delivering albumin-bound Fe(III) to hepatocytes.

29 August 2022 in eJHaem
Verified
Journal Article
Open access
JWJonathan R. A. de Wilde
Jonathan R. A. de Wilde
BDBirgit van Dooijeweert
Birgit van Dooijeweert
AVAnnelies van Vuren
Annelies van Vuren
EHElise J. Huisman
Elise J. Huisman
FSFrans J. Smiers
Frans J. Smiers
MBMarije Bartels
Marije Bartels
In Diamond-Blackfan anaemia (DBA), iron overload (IO) is common in transfusion-dependent patients, yet has also been reported in non-transfusion-dependent patients. We explored the incidence of IO in transfusion-dependent and non-transfusion-dependent DBA patients. We observed hepatic IO in 65% of patients analysed with MRI, including three patients that were only treated with transfusions in the past. Whereas overall ferritin levels and liver iron content correlated, ferritin levels did not reflect total body iron adequately. Our data suggest that transfusion burden in the past plays an important role in IO in DBA, and should be taken into account during follow up.

17 May 2021 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
AVAnnelies van Vuren
Annelies van Vuren
CMCaterina P. Minniti
Caterina P. Minniti
LMLaurel Mendelsohn
Laurel Mendelsohn
JBJohn H. Baird
John H. Baird
GKGregory J Kato
Gregory J Kato
EBEduard J. van Beers
Eduard J. van Beers
Click on the article title to read more.

31 March 2026 in British Journal of Haematology
Verified
Journal Article
Open access
JWJonathan R. A. de Wilde
Jonathan R. A. de Wilde
GKGeoffrey Kuppens
Geoffrey Kuppens
MBMaryse E. Boesveld
Maryse E. Boesveld
AVAnnelies van Vuren
Annelies van Vuren
WSWouter van Solinge
Wouter van Solinge
RWRichard van Wijk
Richard van Wijk
Summary: Hereditary spherocytosis (HS) is a hereditary haemolytic anaemia, caused by pathogenic variants in genes encoding red blood cell membrane proteins. Osmotic gradient ektacytometry evaluates red cell deformability and hydration and is increasingly used in the diagnosis of HS. We retrospectively evaluated laboratory data from 233 HS patients focusing on osmotic gradient ektacytometry parameters, including two novel parameters, O min ‐width and O max ‐width. We found that the maximum elongation index (EI max ), representing the maximum deformability, was decreased in SPTB relative to SLC4A1 and SPTA1 (0.509 vs. 0.557 and 0.564, both p < 0.01). Hydration was most affected in SLC4A1 , with the lowest median O hyper (416 mOsm/kg). The novel parameters also showed differences: O min ‐width was higher in SPTB and ANK1 compared to SLC4A1 and SPTA1 ( p < 0.05). O max ‐width was lowest in SLC4A1 (92 mOsm/kg). We found that non‐missense variants, opposed to missense variants, were associated with decreased deformability in SPTB and ANK1 subgroups as well as with decreased hydration in the ANK1 subgroup specifically (O hyper missense 472 mOsm/kg vs. non‐missense 436 mOsm/kg). Lastly, when classifying disease severity based on reticulocyte production index, we found that O min , EI max , area under the curve (AUC), O min ‐width and O max ‐width differed between mild and moderate patients (all p < 0.05). Our findings suggest that osmotic gradient ektacytometry provides additional information on HS pathophysiology and clinical severity.